
    
      The study consists of 2 parts: Main Study (screening through Week 16) and Long-Term Extension
      (LTE) (up to 1.5 years after Week 16). Participants who permanently discontinue treatment in
      the Main Study will not be eligible for the Long-Term extension.
    
  